ETHOSUXIMIDE

Post-LOE

ethosuximide

Inpharmus

ANDAORALCAPSULE

Approved

May 2008

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

ETHOSUXIMIDE (ethosuximide) by Inpharmus is clinical pharmacology ethosuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. Approved for epilepsy. First approved in 2008.

Drug data last refreshed 20h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Ethosuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of epileptiform attacks is reduced, apparently by depression of the motor cortex and…

Indications (1)

epilepsy

Company

Worked on ETHOSUXIMIDE at Inpharmus? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.